Business, energy, technology, markets and global industry news from Business News Today

CTX310

PharmaDeviceNews CTX310
Representative image: Laboratory monitoring of gene-editing and lipid data as CRISPR Therapeutics reports one-year CTX310 results showing durable ANGPTL3, triglyceride and LDL cholesterol reductions after a single in vivo CRISPR treatment.
Pharma & Biotech

CTX310 delivers one-year lipid reductions as CRISPR Therapeutics advances in vivo cardiovascular editing

CTX310 sustains deep ANGPTL3, LDL and triglyceride reductions for one year after one infusion. See what the data mean for CRISPR Therapeutics.

Read More